AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acute Lymphoblastic Leukemia
  • Age: Between 2 - 21 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. 1. Newly diagnosed de novo ALL (B-ALL or T-ALL) or mixed phenotypic acute leukemia (MPAL meeting 2016 WHO definition) with definitive evidence of BCR-ABL1 fusion by karyotype, FISH and/or RT-PCR.
    2. 2. Patient must have previously started Induction therapy, which includes vincristine, a corticosteroid, pegaspargase, with or without anthracycline, and/or other standard cytotoxic chemotherapy.
    3. 3. Patients must have a performance status corresponding to ECOG scores of 0, 1, or 2

You may not be eligible for this study if the following are true:

    1. 1. Known history of chronic myelogenous leukemia (CML).
    2. 2. Active, uncontrolled infection or active systemic illness that requires ongoing vasopressor support or mechanical ventilation.
    3. 3. Down Syndrome
    4. 4. Pregnancy and Breast Feeding.



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.